Published in Otolaryngol Clin North Am on May 25, 2013
Cancer of the oral cavity. Surg Oncol Clin N Am (2015) 0.85
The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. Oncotarget (2016) 0.75
Short-term Intervention to Revert Premalignant Lesions as Strategy to Prevent Gastrointestinal Cancers. J Cancer Prev (2013) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (1953) 11.45
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med (1996) 10.09
HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol (2010) 6.53
Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet (2005) 5.15
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med (2007) 4.72
A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood (2002) 4.59
Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer (1984) 4.46
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 3.69
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res (1993) 3.62
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc (2010) 3.44
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med (2008) 2.82
EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst (2000) 2.77
Criteria for grading in the Ljubljana classification of epithelial hyperplastic laryngeal lesions. A study by members of the Working Group on Epithelial Hyperplastic Laryngeal Lesions of the European Society of Pathology. Histopathology (1999) 2.76
Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res (2000) 2.71
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Is diagnostic delay related to advanced-stage oral cancer? A meta-analysis. Eur J Oral Sci (2009) 2.34
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med (1996) 2.29
Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res (1999) 2.24
Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med (2008) 2.24
Premalignant lesions of the oral mucosa. A discussion about the place of oral intraepithelial neoplasia (OIN). Oral Oncol (2002) 2.21
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst (2005) 2.04
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin (2012) 2.00
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck (2009) 1.98
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol (2009) 1.97
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res (2005) 1.81
Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev (2010) 1.81
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res (2002) 1.75
Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol (2001) 1.72
Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol (2006) 1.65
Oral leukoplakia status six weeks after cessation of smokeless tobacco use. J Am Dent Assoc (1999) 1.58
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) (2009) 1.57
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) (2011) 1.53
Field cancerization in the aerodigestive tract--its etiology, manifestation, and significance. J Otolaryngol (1984) 1.43
Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res (2009) 1.40
Squamous cell carcinoma of the head and neck in never smoker-never drinkers: a descriptive epidemiologic study. Head Neck (2008) 1.39
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) (2008) 1.32
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Effect of cessation of tobacco use on the incidence of oral mucosal lesions in a 10-yr follow-up study of 12,212 users. Oral Dis (1995) 1.24
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res (2008) 1.23
Malignant transformation of oral leukoplakia: a retrospective cohort study of 218 Chinese patients. BMC Cancer (2010) 1.22
Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol (2009) 1.22
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst (1997) 1.19
Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay? Oral Dis (2010) 1.18
Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res (1995) 1.15
Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res (2008) 1.14
Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res (1994) 1.14
Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer (2005) 1.13
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
Laser surgery as a treatment for oral leukoplakia. Oral Oncol (2003) 1.12
Different impact from betel quid, alcohol and cigarette: risk factors for pharyngeal and laryngeal cancer. Int J Cancer (2005) 1.11
The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med (1999) 1.10
Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res (1999) 1.10
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) (2010) 1.10
Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc (2008) 1.09
A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res (2000) 1.08
Mouse models for human head and neck squamous cell carcinomas. Head Neck (2006) 1.07
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer (2008) 1.06
Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol (2007) 1.05
The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) (2011) 1.02
Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila) (2010) 1.00
Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med (2008) 1.00
Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst (1994) 1.00
Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc (2011) 0.99
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res (2009) 0.97
Photodynamic therapy of malignant and premalignant lesions in patients with 'field cancerization' of the oral cavity. J Laryngol Otol (1993) 0.97
Habitual risk factors for head and neck cancer. Otolaryngol Head Neck Surg (2004) 0.97
Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev (2001) 0.95
Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol (1998) 0.94
An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies. Carcinogenesis (2005) 0.93
Effect on oral leukoplakia of reducing or ceasing tobacco smoking. Acta Derm Venereol (1982) 0.92
COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer (2001) 0.91
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci (2003) 0.91
In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res (2009) 0.91
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) (2009) 0.90
Profiling clonality and progression in multiple premalignant and malignant oral lesions identifies a subgroup of cases with a distinct presentation of squamous cell carcinoma. Clin Cancer Res (2001) 0.88
A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers. Cancer Epidemiol Biomarkers Prev (2011) 0.88
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res (2010) 1.54
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res (2008) 1.23
Management of odontogenic keratocysts of the jaws: a ten-year experience with 120 consecutive lesions. J Craniomaxillofac Surg (2009) 1.09
Extensive ameloblastic fibroma in an adolescent patient: a case report with a follow-up of 4 years. Eur J Dent (2009) 1.06
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther (2010) 1.03
Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol (2015) 0.99
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer (2009) 0.96
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res (2013) 0.95
EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One (2012) 0.94
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. Hepatology (2014) 0.94
Florid osseous dysplasia: report of a case presenting acute cellulitis. Med Oral Patol Oral Cir Bucal (2009) 0.94
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) (2011) 0.92
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) (2012) 0.92
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.90
Mandibular cuniculatum carcinoma: apropos of 3 cases and literature review. Head Neck (2010) 0.90
Necrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report. Head Neck (2007) 0.89
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) (2009) 0.87
Case study: effectiveness of plasma exchange in an adolescent with systemic lupus erythematosus and catatonia. J Am Acad Child Adolesc Psychiatry (2003) 0.86
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics (2014) 0.85
Severe facial rubber bullet injuries: less lethal but extremely harmful weapons. Injury (2010) 0.85
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther (2013) 0.84
An asymptomatic radiolucent lesion of the maxilla. Clear cell odontogenic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.83
p16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck. Head Neck (2012) 0.82
Proliferative verrucous leukoplakia (PVL): a review of an elusive pathologic entity! Adv Anat Pathol (2013) 0.81
Postoperative complications of fibular free flaps in mandibular reconstruction: an analysis of 25 consecutive cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 0.81
Heterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED). Am J Transl Res (2009) 0.81
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck (2014) 0.81
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol (2012) 0.81
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol (2013) 0.80
Proliferative verrucous leukoplakia: recognition and differentiation from conventional leukoplakia and mimics. Head Neck (2014) 0.80
Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat (2013) 0.78
Erythropoietin-producing lung cancer. Intern Med (2009) 0.77
Statins: a new pharmacological agent for free flap surgery? J Plast Reconstr Aesthet Surg (2009) 0.77
The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am (2013) 0.75
Ewing's sarcoma of jaw bones in adult patients: 10-year experiences in a Paris university hospital. J Craniomaxillofac Surg (2008) 0.75
Pathology Quiz Case 1. Keratocystic odontogenic tumor (KCOT). Arch Otolaryngol Head Neck Surg (2009) 0.75
Head and neck lesions of Kimura's disease: exclusion of human herpesvirus-8 and Epstein-Barr virus by in situ hybridisation and polymerase chain reaction. An immunohistochemical study. J Craniomaxillofac Surg (2009) 0.75
Chemotherapy for recurrent/metastatic head and neck cancers. Anticancer Drugs (2017) 0.75
Late cerebellar relapse of a juvenile bronchial carcinoid. Clin Lung Cancer (2007) 0.75
Chemotherapy for localized head and neck squamous cell cancers. Anticancer Drugs (2017) 0.75
Direct laryngoscopy should be procedure of choice in the airway management of patients with dental cellulitis. Eur J Anaesthesiol (2012) 0.75